HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma

• Published in: Cell death discovery 2024-07, Vol.10 (1), p.338-12, Article 338
• Main Authors: Contenti, J., Guo, Y., Larcher, M., Mirabal-Ortega, L., Rouleau, M., Irondelle, M., Tiroille, V., Mazzu, A., Duranton-Tanneur, V., Pedeutour, F., Ben-Sahra, I., Lago, C., Leva, G., Tiberi, L., Robert, G., Pouponnot, C., Bost, F., Mazure, N. M.
• Format: Article
• Language: English
• Subjects: 631/154/53/2423; 631/443/319/320; 631/67/1857; 631/67/2332; 631/80/82/23; Apoptosis; Biochemistry; Biomedical and Life Sciences; Cancer; Cell Biology; Cell Cycle Analysis; Cell death; DNA methylation; Electron transport chain; Hypoxia; Hypoxia-inducible factor 1; Hypoxia-inducible factor 1a; Life Sciences; Localization; Medical prognosis; Medulloblastoma; Metabolism; Metastases; Metformin; NADH-ubiquinone oxidoreductase; Post-translation; Stem Cells; Toxicity; Tumors
• ISSN: 2058-7716; 2058-7716
• DOI: 10.1038/s41420-024-02100-5

Medulloblastoma (MB) is the most prevalent brain cancer in children. Four subgroups of MB have been identified; of these, Group 3 is the most metastatic. Its genetics and biology remain less clear than the other groups, and it has a poor prognosis and few effective treatments available. Tumor hypoxia and the resulting metabolism are known to be important in the growth and survival of tumors but, to date, have been only minimally explored in MB. Here we show that Group 3 MB tumors do not depend on the canonical transcription factor hypoxia-inducible factor-1α (HIF-1α) to mount an adaptive response to hypoxia. We discovered that HIF-1α is rendered inactive either through post-translational methylation, preventing its nuclear localization specifically in Group 3 MB, or by a low expression that prevents modulation of HIF-target genes. Strikingly, we found that HIF-2 takes over the role of HIF-1 in the nucleus and promotes the activation of hypoxia-dependent anabolic pathways. The exclusion of HIF-1 from the nucleus in Group 3 MB cells enhances the reliance on HIF-2’s transcriptional role, making it a viable target for potential anticancer strategies. By combining pharmacological inhibition of HIF-2α with the use of metformin, a mitochondrial complex I inhibitor to block respiration, we effectively induced Group 3 MB cell death, surpassing the effectiveness observed in Non-Group 3 MB cells. Overall, the unique dependence of MB cells, but not normal cells, on HIF-2-mediated anabolic metabolism presents an appealing therapeutic opportunity for treating Group 3 MB patients with minimal toxicity.